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Abstract
Background—Genome-wide association studies (GWAS) identified variants at 19p13.1 and
ZNF365 (10q21.2) as risk factors for breast cancer among BRCA1 and BRCA2 mutation carriers,
respectively. We explored associations with ovarian cancer and with breast cancer by tumor
histopathology for these variants in mutation carriers from the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA).
Methods—Genotyping data for 12,599 BRCA1 and 7,132 BRCA2 mutation carriers from 40
studies were combined.
Results—We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for
BRCA1 mutation carriers (hazard ratio (HR)=1.17; 95%CI 1.07–1.27; p=7.42×10−4) and between
rs16917302 at ZNF365 (HR=0.84; 95%CI 0.73–0.97; p=0.017) but not rs311499 at 20q13.3
(HR=1.11; 95%CI 0.94–1.31; p=0.22) and breast cancer risk for BRCA2 mutation carriers.
Analyses based on tumor histopathology showed that 19p13 variants were predominantly
associated with estrogen receptor (ER)-negative breast cancer for both BRCA1 and BRCA2
mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast
cancer for both BRCA1 and BRCA2 mutation carriers. We also found for the first time that
rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1
(HR=1.16; 95%CI 1.05–1.29; p=3.8×10−4) and BRCA2 mutation carriers (HR=1.30; 95%CI
1.10–1.52; p=1.8×10−3).
Conclusions—19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes
of breast cancer among BRCA1 and BRCA2 mutation carriers.
Impact—These findings can lead to an improved understanding of tumor development and may
prove useful for breast and ovarian cancer risk prediction for BRCA1 and BRCA2 mutation
carriers.
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Introduction
Genome-wide association studies (GWAS) have been used to identify several loci
containing common variants that are associated (p<1.0×10−7) with breast cancer risk in the
general population. Variants from twelve of these loci have also been investigated as
modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers (1–3). While only variants
in CASP8, TOX3, 2q35, and 6q25.1 have been associated with breast cancer risk in BRCA1
mutation carriers, variants in FGFR2, TNRC9/TOX3, MAP3K1, LSP1, 2q35, SLC4A7/
NEK10, 5p12 and 1p11.2 loci have been associated with breast cancer in BRCA2 mutation
carriers (1–3). This is consistent with the known associations between these SNPs and
estrogen receptor (ER) status of breast cancers in the general population (4).
Most recently, a GWAS of BRCA1 mutation carriers conducted through CIMBA identified
five SNPs on 19p13 that were associated with breast cancer risk for BRCA1 mutation
carriers (5). Two of these showed independent associations (rs8170 hazard ratio (HR)=1.26;
95%CI 1.17–1.35; Ptrend = 2.3×10−9 and rs2363956 HR=0.84; 95%CI 0.80–0.89;
Ptrend=5.5×10−9). Imputation analysis of the 19p13 region, using 1000 Genomes Project
data, identified several correlated SNPs with more significant associations than rs8170 and
rs2363956. The 19p13.1 locus was also found to be associated with ER negative breast
cancer (rs8170 OR=1.21, p=0.003) and triple negative breast cancer (tumors lacking
expression of ER, progesterone receptor (PR), and human epidermal growth factor receptor
2 (HER2)) (rs8170 OR=1.28, p=1.2×10−6) in the general population (5). In addition, the
19p13.1 locus has been associated with ovarian cancer in the general population (rs8170
OR=1.12; p=3.6×10−6) (6), but was not found to be associated with ovarian cancer in
BRCA1 mutation carriers (rs8170 HR=1.07; p=0.33) (5). A separate GWAS in BRCA2
mutation carriers identified two breast cancer susceptibility alleles (rs16917302 at ZNF365
(10q21.2), HR=0.75; 95%CI 0.66–0.86; p=3.8×10−5 and rs311499 at 20q13.33, HR=0.72;
95%CI 0.61–0.85; p=6.6×10−5) (7). A weakly correlated SNP at the ZNF365 locus
(rs10995190) has also been associated with breast cancer overall (OR=0.83; p=5.1 × 10−15)
and ER positive (p=4.1×10−6) but not ER negative breast cancer in the general population
(8).
Here, we genotyped more than 12,000 BRCA1 and 7,000 BRCA2 mutation carriers from the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), for the previously
genotyped variant at 19p13.1, rs8170, and one of the imputed SNPs that was found to have a
stronger association with breast cancer risk for BRCA1 mutation carriers (rs67397200). We
also genotyped SNPs at ZNF365 (rs16917302), and 20q13.3 (rs311499) in an effort to verify
these loci as risk factors for ovarian cancer and to further validate these loci as risk factors
for breast cancer in BRCA1 and BRCA2 mutation carriers.
Materials and Methods
Subjects
All mutation carriers participated in clinical or research studies at the host institutions under
ethically approved protocols and provided written informed consent. Subjects were BRCA1
and BRCA2 mutation carriers recruited by 40 study centers in 22 countries and assembled
through the CIMBA initiative (Supplementary Table 1). The majority were recruited
through cancer genetics clinics and enrolled into national or regional studies. Others were
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identified in research studies of high-risk families, by population-based sampling of cases
and some by community recruitment. Eligibility to participate in CIMBA is restricted to
female carriers of pathogenic BRCA1 or BRCA2 mutations, defined by generally
recognized criteria (Breast Cancer Information Core), who were 18 years old or older at
recruitment. Information collected included the year of birth; mutation description
(including nucleotide position and base change); age at last follow-up; ages at breast and
ovarian cancer diagnoses; and age or date at bilateral prophylactic mastectomy. Information
was also available on the country of residence. Related individuals were identified through a
unique family identifier. Women with pathogenic mutations in both BRCA1 and BRCA2
were excluded from the current analysis. The primary analysis was restricted to women self-
reported as “white European”. Overlap of carriers between studies was evaluated by
comparing the year of birth, exact mutation description, the reported ages, and previous SNP
genotype data available within the CIMBA database. Duplicated mutation carriers were
included only once in the analysis.
Genotyping
Rs311499 at 20q13.3, rs16917302 at ZNF365 and both rs8170 and rs67397200 at 19p13.1
were genotyped using the iPLEX Mass Array platform at four genotyping centers as part of
a larger study of 24 candidate SNPs. All centers included at least 2% duplicate samples and
a random mixture of affected and unaffected carriers on each plate. Samples that failed for
five or more of the SNPs genotyped were excluded from the analysis. Studies with a SNP
call rate of <95% were excluded from the analysis of the SNP. The concordance between
duplicates had to be at least 98%. To assess the accuracy of genotyping across genotyping
centers, all centers genotyped 95 DNA samples from a standard test plate (Coriell Institute)
for all SNPs. Genotyping centers with more than one concordance failure on the test plate
for a SNP were excluded for analyses of that SNP. Deviation from Hardy-Weinberg
equilibrium (HWE) was assessed for unrelated subjects separately for each SNP and study.
The observed genotype frequencies were not significantly different from the expected under
HWE for any of the SNPs and studies. After the above exclusions, a total of 19,731 unique
mutation carriers (12,599 BRCA1 and 7,132 BRCA2) from 40 studies had an observed
genotype for at least one SNP (Supplementary Table 1).
Tumor pathology data collection
Tumor pathology data were collected from patient pathology reports, medical records,
pathology review data, tumor registry records and results from tissue microarrays. ER status
was identified as negative or positive, with immunohistochemistry scoring data and
methodology provided when available. Most studies applied a cut-off of >10% tumor cells
stained positive for ER positive status. For a small number of cases, where other scoring
methods based on the proportion and intensity of staining were applied (Allred score,
Remmele score and H-score), widely-accepted cut-offs were used. Consistency checks were
performed to validate receptor data against supplementary scoring information if provided.
Statistical analysis
The aim of the primary analysis was to evaluate the association between each genotype and
breast cancer risk. We conducted the analysis by modelling the retrospective likelihood of
the observed genotypes conditional on the disease phenotypes as previously described (9).
The phenotype of each individual was defined by age at diagnosis of breast cancer or age at
last follow-up. Individuals were censored at the earliest of age of first breast cancer
diagnosis, ovarian cancer diagnosis, bilateral prophylactic mastectomy or age at last
observation. Mutation carriers censored at ovarian cancer diagnosis were considered
unaffected in the analysis of breast cancer. The effect of each SNP was modelled either as a
per-allele HR (multiplicative model) or as separate HRs for heterozygotes and homozygotes.
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We used a Cox proportional-hazards model and tested the assumption of proportional
hazards by adding a “genotype×age” interaction term in order to fit models in which the HR
changed with age. We examined heterogeneity across studies by comparing models that
allowed for study-specific log-hazard ratios against models in which the same log-hazard
ratio was assumed to apply to all studies. All analyses were stratified by country of
residence and applied cohort specific breast cancer incidence rates for BRCA1 and BRCA2
(10). A robust variance-estimation approach was used to adjust for the non-independence
among related carriers.
To evaluate the evidence of replication for each of the SNPs, analyses were restricted to
mutation carriers who had not been used in any of the previous BRCA1 and BRCA2 studies.
The number of new samples used in each of the SNP analyses are shown in Supplementary
Table 2. In addition, analysis were performed using all available BRCA1 and BRCA2
carriers. The combined effects of the SNPs on breast cancer risk, were evaluated by fitting
retrospective likelihood models while allowing for linkage disequilibrium between the loci.
To test for potential effects of survival bias, prevalent cases, defined as mutation carriers
diagnosed more than five years prior to the age at recruitment, were excluded. Associations
with specific functional class of mutation were also assessed. Class 1 mutations are
predicted to undergo nonsense mediated RNA decay resulting in reduced levels of mutant
transcript while Class 2 mutations are predicted to generate stable mutant proteins (11). The
associations with breast cancer subtypes defined by the estrogen receptor (ER) status of the
tumors in BRCA1 and BRCA2 mutation carriers were assessed by an extension of the
retrospective likelihood approach that models the simultaneous effect of each SNP on more
than one tumor subtype (12). Associations with ovarian cancer risk were evaluated within a
competing risk analysis framework (13) by estimating HRs simultaneously for breast and
ovarian cancers. Since each mutation carrier was at risk of breast and ovarian cancer we
assumed that the probabilities of developing each disease were independent conditional on
the underlying genotype. In this analysis, individuals were followed to the age of the first
breast or ovarian cancer diagnosis and were considered to have developed the corresponding
disease. Individuals were censored for breast cancer at the age of bilateral prophylactic
mastectomy and for ovarian cancer at the age of bilateral oophorectomy and were assumed
to be unaffected for the corresponding disease. The remaining individuals were censored at
the age at last observation and were assumed to be unaffected for both diseases.
Results
After quality control exclusions, genotype data from 12,599 BRCA1 and 7,132 BRCA2
mutation carriers including 5,408 BRCA1 and 3,780 BRCA2 mutation carriers not studied
in the original GWAS were available for analysis. Of the BRCA1 mutation carriers, 6,390
were affected with breast cancer and 6,209 were considered unaffected in the breast cancer
analysis (censored at bilateral prophylactic mastectomy, ovarian cancer, or age at last follow
up). Similarly, among the BRCA2 mutation carriers, 3,810 were affected with breast cancer
and 3,322 were unaffected. The characteristics of these mutation carriers are shown in Table
1 and the origins of the samples are summarized in Supplementary Table 1.
The associations between breast cancer risk in BRCA1 and BRCA2 mutation carriers and
the minor alleles of rs8170 and rs67397200 (19p13.1), rs16917302 (ZNF365), and rs311499
(20q13.33) are summarized in Table 2. The minor allele of rs8170 at 19p13.1 was strongly
associated with risk of breast cancer in BRCA1 mutation carriers (HR=1.20; 95%CI 1.13–
1.28; p=8.7×10−9) but not BRCA2 mutation carriers. This result for 12,599 BRCA1
mutation carriers was consistent with the original finding in the BRCA1 GWAS using 8,363
BRCA1 mutation carriers (HR=1.26; 95%CI 1.17–1.35; p=2.3×10−9). A separate analysis
restricted to carriers not used in the BRCA1 GWAS also confirmed the association
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(HR=1.17; 95%CI 1.07–1.27; p=7.42×10−4) (Supplementary Table 2). Similarly,
rs67397200 at 19p13.1, which was imputed in the BRCA1 GWAS, was strongly associated
with breast cancer risk in BRCA1 carriers (HR=1.17; 95%CI 1.11–1.23; p=2.4×10−8) (Table
2). There was no evidence of heterogeneity in the HRs across studies for BRCA1 mutation
carriers (Figure 1). However, there was evidence that the per-allele HRs in BRCA1 mutation
carriers for rs8170 (p=0.015) and rs67397200 (p=0.007) at 19p13.1 decreased with
increasing age of diagnosis of breast cancer. Since rs8170 and rs67397200 are located in the
same region of 19p13.1 (r2=0.58), we conducted an analysis for the joint effects of these
SNPs on breast cancer risk in BRCA1 mutation carriers (n=10,173). When accounting for
haplotype structure, rs67397200 remained significant (P for inclusion=2.75×10−3) and was
retained in the model, whereas rs8170 was excluded (P for inclusion=0.18). Rs8170 and
rs67397200 were not associated with breast cancer risk for BRCA2 mutation carriers (Table
2).
Among SNPs identified from the original BRCA2 GWAS, an analysis of genotype data
from 7,132 BRCA2 mutation carriers confirmed that rs16917302 at the ZNF365 locus was
associated with a decreased risk of breast cancer (HR=0.83; 95%CI 0.75–0.93; p=7.0×10−4).
The association also replicated in the additional carriers, not previously included in the
BRCA2 GWAS (HR=0.84; 95%CI 0.73–0.97; p=0.017) (Supplementary Table 2). In
contrast, rs311499 from 20q13.3, which was associated with breast cancer risk in the
BRCA2 GWAS (HR=0.72; 95%CI 0.61–0.85; p=6.6×10−5) (7), was not associated with risk
of breast cancer in BRCA2 carriers in the overall analysis (HR=0.95; 95%CI 0.84–1.07;
p=0.36 (Table 2) nor the replication study (HR=1.11; 95%CI 0.94–1.31; p=0.22)
(Supplementary Table 2). There was no evidence for heterogeneity in the HRs across studies
for BRCA2 mutation carriers (Figure 1). HRs for rs16917302 and rs311499 did not vary by
age at diagnosis.
To determine whether the inclusion of long-term survivors influenced the results, we
repeated our analyses of the four SNPs, excluding BRCA1 and BRCA2 mutation carriers
diagnosed with breast cancer more than five years before recruitment (prevalent cases). The
strength of the associations for rs16917302 at ZNF365 (per-allele HR=0.85) for BRCA2
mutation carriers, and for rs8170 (per-allele HR=1.19) and rs67397200 at 19p13.1 (per-
allele HR=1.16) for BRCA1 mutation carriers were essentially unchanged (Supplementary
Table 3). There was no influence of mutation type for BRCA1 mutation carriers on breast
cancer risk in the associations between mutations conferring susceptibility to nonsense
mediated RNA decay (NMD) (Class 1) and missense or truncating mutations not triggering
NMD (Class 2) for any of the SNPs (Supplementary Table 4).
Breast tumors in BRCA1 mutation carriers are predominantly ER-negative (14) and rs8170
from 19p13.1 is strongly associated with ER-negative but not ER-positive breast cancer in
the general population (5). Because of these previous findings, we evaluated whether rs8170
and rs67397200 at 19p13.1, as well as rs311499 at 20q13.3 and rs16917302 at ZNF365,
were differentially associated with ER-positive and/or ER-negative tumor status in BRCA1
and BRCA2 mutation carriers. Although the stratified results suggested a slightly stronger
association for the 19p13.1 rs67397200 SNP with ER-negative disease than with ER-
positive disease in BRCA1 mutation carriers (per allele ER-negative HR=1.22; 95%CI 1.14–
1.30; p=4.4×10−9; per allele ER-positive HR=1.14; 95%CI 1.01–1.30; p=0.040), the
difference was not significant (p=0.41) (Table 3). Rs67397200, however, was associated
with ER-negative disease (per allele HR=1.29; 95%CI 1.11–1.49; p=8.7×10−4) but not ER-
positive disease (per allele HR=0.92; 95%CI 0.85–1.01; p=0.074) in BRCA2 mutation
carriers (p-heterogeneity= 1.5×10−4) (Table 3). The lack of association with rs311499 at
20q13.3 did not vary by ER-status in BRCA1 or BRCA2 mutation carriers. For BRCA2
mutation carriers, the minor allele of rs16917302 at ZNF365 was inversely associated with
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both ER-positive (per allele HR=0.86; 95%CI 0.75–0.97; p=0.016) and ER-negative tumors
(per allele HR=0.79; 95%CI 0.62–1.00; p=0.048) (p-heterogeneity=0.56) (Table 3).
However, in BRCA1 mutation carriers rs16917302 was associated with ER-positive (per
allele ER-positive HR=0.77; 95%CI 0.62–0.95; p=0.016), but not ER-negative status (p-
heterogeneity=0.028) (Table 3).
BRCA1 and BRCA2 mutations are associated with elevated risk of ovarian cancer. In this
CIMBA study 1,465 BRCA1 mutation carriers and 453 BRCA2 mutation carriers who
developed ovarian cancer were also genotyped for the four SNPs under study. To assess the
influence of these SNPs on ovarian cancer risk in BRCA1 and BRCA2 mutation carriers we
used a competing risk analysis that evaluated the associations with breast and ovarian cancer
risk simultaneously. While previous studies did not detect an association between rs8170 at
19p13.1 and ovarian cancer in BRCA1 or BRCA2 mutation carriers (5), in this competing
risk analysis with larger numbers of BRCA1 and BRCA2 mutation carriers, rs8170 was
significantly associated with ovarian cancer risk in both BRCA1 (HR=1.15; 95%CI 1.03–
1.29; p=0.015) and BRCA2 (HR=1.34; 95%CI 1.12–1.62; p=1.9×10−3) mutation carriers
(Table 4). Similarly rs67397200 at 19p13.1 was associated with ovarian cancer risk in both
BRCA1 (HR=1.16; 95%CI 1.05–1.29; p=3.8×10−4) and BRCA2 (HR=1.30; 95%CI 1.10–
1.52; p=1.8×10−3) mutation carriers (Table 4). Rs311499 at 20q13.3 and rs16917302 at
ZNF365 were not associated with ovarian cancer risk for either BRCA1 or BRCA2 mutation
carriers (Table 4).
Discussion
GWAS of BRCA1 and BRCA2 mutation carriers previously identified variants at 19p13.1,
ZNF365 and 20q13.3 as candidate breast cancer risk modifiers (5, 7). In this study, we
further evaluated associations between variants at these loci and both breast and ovarian
cancer in BRCA1 and BRCA2 mutation carriers. For the first time, we found that both
rs8170 and the previously imputed rs67397200 at 19p13.1 were strongly associated with
ovarian cancer in both BRCA1 and BRCA2 mutation carriers. In addition, we found that
rs8170 and rs67397200 at 19p13.1 were associated with breast cancer risk for BRCA1 and
rs16917302 at ZNF365 was associated with breast cancer in BRCA2 mutation carriers in
this replication study using an independent set of mutation carriers and in the combined
analyses of data from the original study and the replication study. In contrast, rs311499 at
20q13.3 showed no association with breast cancer in the replication study. We also report
for the first time that the BRCA1 GWAS SNP rs67397200 is associated with ER-negative
breast cancer in BRCA2 mutation carriers and that the BRCA2 GWAS SNP rs16917302 is
associated with ER-positive disease in BRCA1 mutation carriers.
The GWAS for breast cancer in BRCA1 mutation carriers originally identified significant
associations between variants at the 19p13.1 locus and risk of breast cancer. Five SNPs
including rs8170 from a 39 kb region were associated with risk of disease. In an analysis of
joint effects of these SNPs on breast cancer risk, the best model included rs8170 or
rs4808611 and rs8100241 or rs2363956 (P for inclusion=7.7×10−5 and P=6.7×10−5 for
rs8170 and rs8100241, respectively) (5), suggesting that the associations were driven by a
single causative variant partially correlated with all five SNPs. Imputation of additional
SNPs in the region from the 1000 Genome Project identified eight perfectly correlated SNPs
within a 13-kb region that were more significantly associated with breast cancer risk. Of
these, we chose rs67397200, which has an r2=0.58 with rs8170 and r2=0.37 with rs8100241/
rs2363956, for further genotyping in an effort to determine whether this SNP (or one of the
seven other highly correlated SNPs) exhibited stronger associations with breast cancer. In an
analysis of rs8170 in 11,669 and rs67397200 in 10,312 BRCA1 mutation carriers, we
observed similarly strong associations with breast cancer for BRCA1 mutation carriers. In a
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joint analysis of rs8170 and rs67397200, allowing for haplotype structure, only rs67397200
remained significant. We were unable to genotype some of the original GWAS SNPs
(rs2363956/rs8100241) in the present study and, as a consequence, could not evaluate the
joint associations with rs67397200. It is therefore still unclear whether rs67397200 accounts
solely for the association signal. The 35kb region containing rs8170 and rs67397200
includes the ABHD8 (abhydrolase domain containing 8), ANKLE1 (ankyrin repeat and
LEM domain containing 1) and C19orf62 genes. C19orf62, encodes MERIT40 (Mediator of
Rap80 Interactions and Targeting 40 kD), a BRCA1 interacting protein that forms a
complex with BRCA1-BARD1, Abraxas1, RAP80, BRCC36 and BRCC45 and is required
for recruitment and retention of the BRCA1-BARD1 ubiquitin ligase at sites of DNA
damage (15). Because alterations in MERIT40 expression or function may modify BRCA1
activity, variants in the C19orf62 locus are attractive candidate breast cancer risk modifiers.
However, since rs67397200 and the seven other imputed SNPs, that showed the most
significant associations with breast cancer risk in BRCA1 mutation carriers, are located at
the 3’ end of ANKLE1 near ABHD8 it is also possible that one of these genes rather than
C19orf62 is influenced by the underlying causative variants in this region. Further
comprehensive genotyping of other common variants and/or rare SNPs from this locus and
detailed functional studies will be required to resolve this issue.
Our GWAS for breast cancer in BRCA2 mutation carriers previously identified strong
associations between rs16917302 in the ZNF365 (dbGENE id: 22891) locus and breast
cancer (7). We have now replicated this association for BRCA2 mutation carriers.
Rs16917302 is located within intron 4 of ZNF365 and is unique to isoform C, the longest of
the four isoforms created by alternative splicing sites (16). In independent studies,
rs10995195 in ZNF365, which is 27kb upstream from and only weakly correlated (r2=0.1)
with rs16917302, has been associated with breast cancer risk (8) and with mammographic
density (17) in the general population. In addition, a cluster of SNPs located 154kb from
rs16917302 in isoform D of ZNF365 has been associated with Crohn’s disease (18–20), and
the region has also been implicated in family-based linkage analyses with uric acid
nephrolithiasis (21) and hypotrichosis (22). It is unclear whether there is genetic or biologic
linkage between these seemingly disparate phenotypes. Further fine-mapping of the ZNF365
region and functional analyses will be needed to identify the causative variants for each
phenotype and to understand the downstream biological effects.
Likewise, rs311499 at 20q13.3 was associated with breast cancer risk in BRCA2 mutation
carriers in the BRCA2 GWAS (per allele HR=0.72; 95%CI 0.61–0.85; p=6.6×10−5).
However, this association was not confirmed in the replication study described above
(HR=1.11; 95%CI 0.94–1.31; p=0.22) or in the combined analysis of the discovery and
replication stages (HR=0.95; 95%CI 0.84–1.07; p=0.36). This result was not unexpected
because the association between rs311499 and breast cancer did not reach significance
(p<0.05) in Stage 2 of the BRCA2 GWAS (HR=0.86; 95%CI 0.67–1.06; p=0.13) (7).
To further characterize the influence of the 19p13.1 and ZNF365 loci on breast cancer risk,
we assessed the strength of association with ER-negative and ER-positive breast cancer in
BRCA1 and BRCA2 mutation carriers. As reported above, rs67397200 at 19p13.1 was
associated with both ER-negative and ER-positive breast cancer in BRCA1 mutation
carriers, whereas rs8170 at 19p13.1 was only associated with ER-negative disease.
Interestingly, rs67397200 and rs8170 were also associated with ER-negative breast cancer
but not ER-positive breast cancer in BRCA2 mutation carriers. This is consistent with our
previous finding that rs8170 at 19p13.1 is more strongly associated with ER-negative than
ER-positive breast cancer in the general population (5). Given that the majority of BRCA1
breast tumors exhibit a basal breast cancer phenotype (14), it remains to be determined
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whether ER-positive basal cases account for the mild association with ER-positive disease in
BRCA1 mutation carriers.
In contrast, we found that rs16917302 in the ZNF365 locus was associated with both
ERpositive and ER-negative disease in BRCA2 mutation carriers. This was consistent with
associations for both ER-positive and ER-negative breast cancer in a recent GWAS of breast
cancer cases with a family history of the disease (8). In contrast, among BRCA1 mutation
carriers the association with breast cancer risk was restricted to ER-positive cases. This
suggests that refinement of phenotype, perhaps in specific subpopulations, may result in
detection of previously hidden associations.
Ovarian cancer is an important component of the cancer phenotype in both BRCA1 and
BRCA2 mutation carriers. Because breast and ovarian cancer can occur in the same
mutation carriers, it has been suggested that susceptibility SNPs common to breast and
ovarian cancer may exist in these populations. However, to date none of the SNPs associated
with breast cancer risk in BRCA1 or BRCA2 mutation carriers have been associated with
ovarian cancer risk. Similarly, SNPs in the BCN2 locus that are associated with ovarian
cancer risk in BRCA1 and BRCA2 mutation carriers are not associated with breast cancer
risk (13). Furthermore, in the general population, only SNPs in the 8q24 locus are known to
influence both breast and ovarian cancer, and these appear to be independent disease-
specific effects (23). Thus, the recent finding that SNPs at 19p13.1 were associated with
breast cancer in BRCA1 mutation carriers (5) and also with ovarian cancer in the general
population (6) raised the possibility that a locus with common influences on breast and
ovarian cancer does exist. However, the BRCA1 GWAS failed to detect any association for
19p13.1 SNPs with ovarian cancer among BRCA1 mutation carriers (843 ovarian cases)
(HR=1.07; 95%CI 0.93–1.24; p=0.33) (5). Here we re-evaluated associations between
19p13.1 SNPs and ovarian cancer using larger numbers of BRCA1 (n=1312) and BRCA2
(n=429) carriers diagnosed with ovarian cancer. Rs67397200 at 19p13.1 was associated with
ovarian cancer risk in both BRCA1 (HR=1.16; 95%CI 1.05–1.29; p=3.8×10−4) and BRCA2
(HR=1.30; 95%CI 1.10–1.52; p=1.8×10−3) mutation carriers. The magnitude of the effect on
ovarian cancer risk in BRCA1 carriers (HR=1.16) was similar to that observed for breast
cancer. This is the first locus found to influence both breast and ovarian cancer risk in either
BRCA1 or BRCA2 mutation carriers.
Including the SNPs from the present study, six loci are now known to modify the risk of
breast cancer for BRCA1 mutation carriers (CASP8, TOX3, 2q35, 6q25.1, 19p13, and
ZNF365 (ER-positive disease only)) (1–3, 5, 10, 24) and ten loci are known to modify the
risk of breast cancer for BRCA2 mutation carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35,
SLC4A7, 5p12, ZNF365, 1p11.2 and 19p13.1 (ER-negative only)) (5, 7, 10, 24). Taken
together, these SNPs result in large variation in the absolute risk of breast cancer for BRCA1
and BRCA2 mutation carriers and may further improve our ability to provide individualized
risks of breast cancer for BRCA1 and BRCA2 mutation carriers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Forest plots of the associations by country of residence of BRCA1 and BRCA2 mutation
carriers with breast cancer risk overall
(A–C) Squares indicate the country specific per-allele HR estimates for SNPs (A) rs8170 for
BRCA1 mutation carriers, (B) rs67397200 for BRCA1 mutation carriers and (C)
rs16917302 for BRCA2 mutation carriers. The area of the square is proportional to the
inverse of the variance of the estimate. Horizontal lines indicate 95% Confidence Intervals
(CIs).
Couch et al. Page 19
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2012 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Couch et al. Page 20
Table 1
Summary characteristics for the 19,731 eligible BRCA1 and BRCA2 mutation carriers* used in the analysis
Characteristic BRCA1 BRCA2
Unaffected Breast
Cancer
Unaffected Breast
Cancer
Number 6209 6390 3322 3810
Person-Years follow-up 264903 263068 147053 168201
Median Age at Censure (IQR1) 42 (34–50) 40 (34–47) 43 (34–53) 43 (37–50)
Age at Censure, N (%)
<30 1189 (19.2) 691 (10.8) 611 (18.4) 306 (8.0)
30–39 1661 (26.8) 2445 (38.3) 834 (25.1) 1141 (30.0)
40–49 1765 (28.4) 2191 (34.3) 865 (26.0) 1394 (36.6)
50–59 1058 (17.0) 812 (12.7) 566 (17.0) 687 (18.0)
60–69 380 (6.1) 198 (3.1) 302 (9.1) 226 (5.9)
70+ 156 (2.5) 53 (0.8) 144 (4.3) 56 (1.5)
Year of birth, N (%)
<1920 28 (0.5) 30 (0.5) 23 (0.7) 44 (1.2)
1920–29 131 (2.1) 196 (3.1) 99 (3.0) 167 (4.4)
1930–39 369 (5.9) 516 (8.1) 232 (7.0) 430 (11.3)
1940–49 832 (13.4) 1341 (21.0) 458 (13.8) 896 (23.5)
1950–59 1409 (22.7) 1989 (31.1) 691 (20.8) 1160 (60.5)
1960–69 1703 (27.4) 1666 (26.1) 902 (27.2) 868 (22.8)
1970+ 1737 (28.0) 652 (10.2) 917 (27.6) 245 (6.4)
Mutation Class, N (%)
Class 12 4063 (65.4) 3878 (60.7) 3114 (93.7) 3520 (92.4)
Class 22 1780 (28.7) 1973 (30.9) 72 (2.2) 100 (2.6)
Other 366 (5.9) 539 (8.4) 136 (4.1) 190 (5.0)
1
IQR: Interquartile range
2See methods for definitions
*Carriers of self reported European ancestry only.
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